Radiobiological effect of 131I radiolabeled recombinant human epidermal growth factor on nude mice with human breast cancer.
- Author:
Yunchun LI
1
;
Weiyun XU
;
Tianzhi TAN
;
Sheng HE
Author Information
1. Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Breast Neoplasms;
metabolism;
pathology;
radiotherapy;
Cell Line, Tumor;
Drug Delivery Systems;
Epidermal Growth Factor;
biosynthesis;
genetics;
pharmacokinetics;
therapeutic use;
Humans;
Iodine Radioisotopes;
Mice;
Mice, Nude;
Neoplasm Transplantation;
Radiopharmaceuticals;
Random Allocation;
Recombinant Proteins;
biosynthesis;
genetics;
pharmacokinetics;
therapeutic use
- From:
Journal of Biomedical Engineering
2005;22(4):749-753
- CountryChina
- Language:Chinese
-
Abstract:
The radiobiological effect of 131I radiolabeled recombinant human epidermal growth factor (131I-rhEGF) on nude mice with human breast cancer was assessed in this study. The tissue mainly uptaking 131I-rhEGF was found by tissue distribution assay in mice. The radiation breakdown of the tissue greatly collecting 131I-rhEGF was examined by biochemical test and biopsy in nude mice with human breast cancer. The tissue distribution assay of 131I-rhEGF in mice showed that 131I-rhEGF greatly accumulated in kidney, liver, spleen and blood. The biochemical test and biopsy revealed that 131I -rhEGF injected twice (dosing once is analogous to 14.58 GBq in a person with 50 kg, once every 14 days) had an effective killing effect on tumor but had no effect of radiation breakdown on kidney, liver,spleen and blood-cell forming tissue in mice with human breast cancer. Therefore, 131I-rhEGF is a drug unharmful to normal tissues in the course of the receptor-mediated target radiotherapy for breast cancer.
